Commentary on Stanley Cohen and Epidermal Growth Factor  by King, Lloyd E
Commentary on Stanley Cohen and Epidermal
Growth Factor
Lloyd E. King, Jr., M.D., Ph.D.
When Stanley Cohen submitted his Preliminary and Short
Report to the Journal of Investigative Dermatology in May, 1962
[1], he had no idea of the impact epithelial or epidermal growth
factor (EGF) would have on biologic and medical sciences. The
JID was not the first journal that Stanley chose to submit his
short paper on EGF and epidermal keratinization. Reviewers for
an unnamed journal he first selected rejected this paper. These
reviewers concluded that the effects he observed were a fluke
and simply due to using sick animals in the experiments.
Fortunately for the JID and science his paper was accepted with
one reviewer commenting that if the observations were true,
Stanley Cohen would become very famous. The unnamed JID
reviewer’s observations were and are true, and Stanley Cohen is
now famous because he was a co-winner of the 1986 Nobel
Prize for Physiology of Medicine with Rita Levi-Montalcini.
In the decade preceding the JID paper Stanley Cohen had
been working in collaboration with Drs. Levi-Montalcini and
Viktor Hamburger at Washington University (1953–1957). This
group was studying the growth of nerve cells, and in 1956
Stanley purified nerve growth factor from certain mouse
tumors that Levi-Montalcini had shown caused dramatic
growth of the nervous system in chick embryos [2]. In 1958
he found NGF-like activity in mouse salivary glands when he
followed up on his studies showing that snake venom,
modified salivary glands, was a rich source of NGF-like
activity. After moving to Vanderbilt University in 1959 with his
lifelong friend, Sidney Colowick, Stanley continued to work
with mouse salivary gland extracts [3]. He observed that
newborn mice injected with salivary gland extracts had
precocious opening of their eyes and premature eruption of
their incisors [1,3]. The histologic documentation of the effects
of the injected salivary gland extracts on epidermal keratiniza-
tion were thus the findings reported in the JID [1]. To Cohen,
but not many others except the reviewer and Dr. Naomi Kanof,
the Editor of the JID at the time, it seemed clear that ‘‘the
opening of the eyelids of newborn mice was offering some
kind of clue to the mystery of biological timing.’’
Cohen devised an ingeniously simple method for isolating
and purifying mouse EGF in relatively large quantities [4],
which allowed him to determine its primary structure [5].
Thus, EGF became an attractive, biochemically defined,
natural substance to study why mammalian cells grow and
differentiate. EGF was found by Cohen and others to stimulate
the growth of many different types of cells and to enhance a
variety of biologic process [6–10]. Using radioactive EGF,
Cohen and his co-workers determined the existence of specific
EGF receptors that mediated all the known effects of EGF
[6–11]. The EGF receptor was found by his group (Carpenter,
King, Ushiro, and others [11–14]) to contain an EGF-stimulated
protein kinase of the type mediating effects of other hormones
and cancer-inducing viruses [9,10,13,14].
His work played a major role in the subsequent discovery by
other investigators of previously unknown cancer genes and
growth factors [9,10,13–15]. These growth factor and oncogene
studies are now beginning to enter the clinical arena in the areas
of diagnosis and therapy. Although the scientific impact of EGF
[and NGF] has been dazzling, the impact of growth factors on
clinical medicine promise to be even more exciting as the
clinical pharmacology of peptide hormones becomes better
understood. EGF is important in understanding and perhaps
treating skin diseases and corneal wounds [8,16]. However,
alone or in combination with related growth factors such as
alpha TFG, even more impressive clinical effects should be
demonstrated in the next few years. Growth factors also may be
important in the diagnosis and treatment of cancer as has been
shown for alpha TGF and its role in the pathogenesis of a para-
neoplastic syndrome, the Sign of Leser-Trelat [17]. In retrospect,
one would not expect such a small paper to have such a large
scientific impact, but truth does often come in small packages.
I applaud both the reviewers and Dr. Kanof for their insight.
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